Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma

NCT02511405 is registered in ClinicalTrials.gov with Vascular Biogenics Ltd. operating as VBL Therapeutics as lead sponsor.

NCT NCT02511405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02511405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2015
Completion date
September 30, 2018
Enrollment
252 (estimated)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma